Millie
your market intelligence analyst
Search Results
118 results
Your search is now limited to «Takeda» expert search.
ENDPOINTS 11/14/2019 11:32
R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.
More from ENDPOINTS:
PharmTech.com 11/14/2019 09:00
Takeda Pharmaceutical Company opened a new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003, the company announced in a Nov. 5, 2019 press release.
More from PharmTech.com:
Financial Post (Canada) 11/14/2019 06:00
In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24.
More from Financial Post (Canada):
Takeda Pharmaceutical 11/14/2019 04:00
Takeda will not receive any proceeds from the Exchange Offer.
More from Takeda Pharmaceutical:
Business Wire 11/13/2019 07:00
Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease.
More from Business Wire:
FiercePharmaManufacturing 11/08/2019 09:21
RELATED: Takeda swings and misses with Ninlaro in AL amyloidosis, calls off phase 3 trial In February, Takeda withdrew an application to the FDA for approval of Ninlaro as maintenance therapy in patients who have undergone stem-cell transplants ...
More from FiercePharmaManufacturing:
Pharmafile 11/08/2019 05:27
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance treatment of multiple myeloma in adult patients not treated with stem cell transplantation.
More from Pharmafile:
Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years.
More from Pharmaceutical Business Review:
Korean Biomedical Review 11/07/2019 02:12
Takeda Pharmaceutical Korea’s conflict between labor and management is rising to its peak, as the two sides tell extremely different stories over a rumor that the company might sell the “primary business unit.
More from Korean Biomedical Review:
Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.
More from Middle East North Africa Financial Network (MENAFN):
FP Trading Desk (Canada) 11/06/2019 12:00
– Company Leadership to Present 20 Abstracts in Oncology and Nine in Hematology Throughout Conference, Showcasing Takeda’s Unique Expertise in Blood Cancers and Bleeding Disorders – CAMBRIDGE, Mass. & OSAKA, Japan — Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society [...]
Reuters.com 11/05/2019 05:09
Stada buys Takeda drug bundle to boost Russia business.
More from Reuters.com:
FierceMedicalDevices 11/05/2019 03:42
Ipsen grabs new R&D lead as Shire's neuro head leaves amid Takeda takeover.
More from FierceMedicalDevices:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications